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Fas-mediated apoptosisStable overexpression of endothelial nitric oxide synthase (NOS-3) in HepG2 cells (4TO-NOS) leads to increased
nitro-oxidative stress and upregulation of the cell death mediators p53 and Fas. Thus, NOS-3 overexpression has
been suggested as a useful antiproliferative mechanism in hepatocarcinoma cells. We aimed to identify the
underlying mechanism of cell death induced by NOS-3 overexpression at basal conditions and with anti-Fas
treatment. The intracellular localization of NOS-3, the nitro-oxidative stress and the mitochondrial activity
were analysed. In addition, the protein expression proﬁle in 4TO-NOS was screened for differentially expressed
proteins potentially involved in the induction of apoptosis. NOS-3 localization in the mitochondrial outer
membranewas not associatedwith changes in the respiratory cellular capacity, but was related to themitochon-
drial biogenesis increase and with a higher protein expression of mitochondrial complex IV. Nitro-oxidative
stress and cell death in NOS-3 overexpressing cells occurred with the expression increase of pro-apoptotic
genes and a higher expression/activity of the enzymes adrenodoxin reductase mitochondrial (AR) and cathepsin
D (CatD). CatD overexpression in 4TO-NOS was related to the apoptosis induction independently of its catalytic
activity. In addition, CatD activity inhibition by pepstatin A was not effective in blocking apoptosis induced by
anti-Fas. In summary, NOS-3 overexpression resulted in an increased sensitivity to anti-Fas induced cell death,
independently of AR expression and CatD activity.
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Nitric oxide (NO) is a lipophilic, highly diffusible and short-lived
physiological messenger, which regulates a variety of important biolog-
ical processes such as vasodilation, respiration, cell migration, immune
response and apoptosis. NO is produced within cells by nitric oxide
synthase (NOS) using L-arginine as substrate, resulting in the formation
of L-citrulline and the end products of NO oxidation, nitrite and nitrate
[1]. There are three isoforms of NOS: neuronal (nNOS or NOS-1), induc-
ible (iNOS or NOS-2) and endothelial (eNOS or NOS-3). All of them
share similar structures and catalytic modes, but they show different
mechanisms regulating their expression and activities [2]. In addition,
a new NOS isoform was found in the mitochondria, but whether it cor-
responds to one of the known isoforms is a matter of discussion [3–5].
The expression of NOS isoforms, including those constitutively
expressed, may be triggered by different stimuli and in a tissue-
dependent manner. In the liver, NO can be synthesized by the activity
of any of the NOS isoforms [6], but its role is an issue of debate. NO is
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damage, depending on factors such as its concentration or the generat-
ing source. Furthermore, the liver expression of NOS isoforms and the
NO production have been related to cancer development through
pro-/anti-apoptotic activities. NOS-3 may be overexpressed in different
types of tumours, andmaymodulate several cancer-related events such
as angiogenesis, apoptosis, cell cycle, invasion or metastasis [1]. By
contrast, NOS-3 activation has also been associated with the inhibition
of growth and proliferation of hepatoma cells [7]. The molecular
mechanism by which NO exerts this antitumoural activity has been
related to the inhibition of the mitochondrial electron transport chain
and to the induction of nitro-oxidative stress [8,9].
We have previously reported that the NOS-3 overexpression in a
hepatocarcinoma cell line is related to apoptosis induced by nitro-
oxidative stress and up-regulation of p53 oncoprotein and cell death
receptor Fas (or CD95) [10]. Furthermore, the pharmacological modula-
tion of the Fas/Fas ligand (FasL or CD95L) signallingmachinery has been
suggested as a useful therapeutic strategy, but caution is warranted
because administration of agonistic Fas-speciﬁc antibodies [11] or FasL
[12] causes extensive hepatocyte apoptosis and fatal hepatitis in mice.
The increase of Fas-mediated apoptosis may be a promising anticancer
therapy in liver disease [10]. In addition, NO-donor molecules have
shown antitumoral properties in vitro and in vivo [10,13].
In this study, we aimed to investigate the mechanism by which
the stable overexpression of NOS-3 induces cell death in the
hepatocarcinoma cell line HepG2, both in basal conditions and with
anti-Fas treatment.
2. Material and methods
2.1. NOS-3 overexpression and culture conditions
The cell line with stable overexpression of NOS-3 (4TO-NOS) and its
corresponding control cell line (4TO) were obtained and maintained
as described elsewhere [14,10]. The cell culture medium was supple-
mentedwith 2.5mM L-arginine to ensure the NOS substrate availability.
Cells were seeded to a conﬂuence of 150,000 cells/cm2, and the mea-
surements were carried out after 48 h. The cell death-inducing agent
anti-Fas (Anti-Human Fas or CD95; 0.5 μg/ml. MBL, Nagoya, Japan)
was administered 48 h after seeding the cells. Cells were collected 2 h
later. The cell-permeable NOS inhibitor Nω-Nitro-L-arginine methyl
ester hydrochloride (L-NAME; 5 mM. Sigma-Aldrich, Missouri, USA)
and the cathepsin D inhibitor pepstatin A (20 μM or 50 μM; Santa Cruz
Biotechnology, California, USA) were added to the culture medium
24 h after seeding the cells.
2.2. NOS-3 subcellular distribution
For western blot localization analysis, the mitochondrial fraction
was isolated by ultracentrifugation in a discontinuous sucrose gradient
performed with 0.8, 1.0, 1.2, 1.4 and 1.6 M sucrose concentrations
in 2 mM HEPES buffer pH 7.4. This method allows for an efﬁcient puri-
ﬁcation of the mitochondrial fraction and minor contamination with
endoplasmic reticulum [15]. Then, mitochondria were subjected to
enzymatic digestion with trypsin (6 or 20 μg/100 μg protein) or
proteinase-K (10 or 40 μg/100 μg protein). 10 μg of proteinwas separat-
ed by SDS–PAGE, electroblotted onto nitrocellulose membrane, and
sequentially probed with speciﬁc antibodies against MTCO2 (a protein
from the inner mitochondrial membrane) (Life Technologies),
translocase of outer mitochondrial membrane 40 homolog (TOM40)
and NOS-3 (Santa Cruz Biotechnology). The cellular localization of the
NOS-3 proteinwas additionally assessed by using a confocalmicroscope
(LSM 5 Exciter) and a confocal imaging system (ZEN 2008, Carl Zeiss,
Jena, Germany). Cells were ﬁxed and incubated with the primary anti-
bodies anti-NOS-3 (Santa Cruz Biotechnology) and anti-MTCO2
(Abcam, Cambridge, UK). Secondary conjugated antibodies were AlexaFluor 488 and 594 (Life Technologies, California, USA). The speciﬁcity
of the immunoreactivity was veriﬁed by incubating cells without the
primary antibodies. ImageJ software was used to assess the mitochon-
drial localization of NOS-3 (http://imagej.nih.gov/ij/).
2.3. Oxygen consumption
O2 consumption determinations in intact cells or in digitonin-
permeabilized cells were carried out in an oxygraph with a Clark
electrode (Hansatech Instruments, Norfolk, UK) [16]. Brieﬂy, 5 × 106
cells were trypsinized, counted and resuspended in culture medium or
respiration buffer (10 mM MgCl2, 250 mM Sucrose, 20 mM HEPES
pH 7.4, 1 mM ADP, 2 mM KH2PO4), respectively. Oxygen consumption
wasmeasured at 37 °Cwith stirring. 6.25 μMFCCPwas used to uncouple
respiration in intact cells. For polarographic measurements, cells were
permeabilized with 1% digitonin (1.2 μl/106 cells) and the oxygen
consumption was recorded after the addition of substrates and inhibi-
tors for complex I (5 mM Glutamate plus Malate, 2 μM Rotenone),
complex II + III (5 mM Succinate plus Glyceraldehyde-3-P, 0.1 μM
Antimycin A) and complex IV (1.2 mM TMPD, 6 mM KCN).
2.4. Mitochondrial membrane potential
The mitochondrial membrane potential (MMP) was monitored
by using the potential-sensitive ﬂuorescent probe tetramethyl-
rhodamine methyl ester (TMR) (Life Technologies). Brieﬂy, cells were
washed with PBS and further incubated with 10 μM TMR for 20 min.
The registration of the measurement was started with the addition of
5 mM glucose. The ﬂuorescence emitted by TMR (λex = 550 nm,
λem = 570 nm) was detected in situ using a GENios Microplate Reader
(TECAN, Männedorf, Switzerland).
2.5. Quantitative analysis of protein nitration
The quantiﬁcation of protein nitration as a measurement of reac-
tive nitrogen species (RNS) was determined in the mitochondrial
fraction by western blot. The post-translational modiﬁcation 3-
nitrotyrosine was used for this purpose. The protein samples were
separated by SDS–PAGE in non-reducing conditions, transferred to
nitrocellulose membrane, and probed with an anti-3-nitrotyrosine
primary antibody (Sigma-Aldrich) [10]. The data from the densitom-
etry analysis of the 55 kDa protein band were normalized to a total
protein value of 10 μg.
2.6. Nitric oxide production
NO production was determined by the Griess reaction as we previ-
ously described [14]. NO-related end products nitrates and nitrites
were quantiﬁed in the cell culture medium 2 h after anti-Fas adminis-
tration. Nitrite concentrations were accurately determined by a nitrite
calibration curve.
2.7. Determination of mitochondrial reactive oxygen species
Cellular reactive oxygen species (ROS) were detected by using the
ﬂuorescent probes 2,7-dichloroﬂuorescein-diacetate (DCFDA) and
dihydroethidium (DHE) (Life Technologies). The cells were washed
and then incubated with 10 μM DCFDA or 5 μM DHE for 20 min or
10 min, respectively. Measurements were initiated by the addition of
5 mM glucose. The ﬂuorescence emitted by DHE (λex = 510 nm,
λem = 590 nm) and DCFDA (λex = 500 nm, λem = 520 nm) was
assessed in situ using a microplate reader. DHE was not used with L-
NAME because the NOS inhibitor appeared to interact with the probe
(data not shown).
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quantiﬁcation
The expression analysis of the antioxidant and pro-apoptotic
genes was determined by RT–qPCR using a LightCycler 480 System
(Roche, Basel, Switzerland) and the One-Step QuantiTect SYBR-
Green Kit (Qiagen, Limburg, Netherlands). Total cellular RNA was
extracted by using TRIsure reagent (Bioline, London, UK), treated
with RNAse-Free DNase (Promega, Wisconsin, USA), and used
as template for mRNA ampliﬁcation with speciﬁc human
oligodeoxynucleotides designed by Primer3 software (v.0.4.0). The
expression of ribosomal protein L13A (RPL13A) was used as a refer-
ence gene. The primer sequences and positions into the cDNA are
summarized in Table 1. The RNA concentration and its integrity
were conﬁrmed by standard procedures. The PCR reaction was per-
formed in duplicate, by adjusting the annealing temperature to
60 °C and in a ﬁnal volume of 10 μl.
The mitochondrial DNA (mtDNA) quantiﬁcation was also per-
formed by RT–qPCR with the ThermOne™ RT-PCR Premix (RBC,
Taipei, Taiwan). The total cellular DNA extracted using standard pro-
cedures was used as template and was ampliﬁed with speciﬁc
oligodeoxynucleotides for MTCO2 and succinate dehydrogenase
subunit A (SDHA), as previously reported [17]. MtDNA copy number
per cell was calculated using SDHA ampliﬁcation as a reference for
nuclear DNA content.2.9. Mitochondrial protein expression analysis
Expression analysis for mitochondrial proteins from respiratory
complexes was assessed by western blot. 40 μg from the total cellular
proteins was separated by SDS–PAGE, then transferred to nitrocellulose
membrane, and ﬁnally probed with primary antibodies anti-NDUFB6
(complex I), anti-SDHB (complex II), anti-UQCRC2 (complex III) and
anti-MTCO2 (complex IV), respectively (Life Technologies). The densi-
tometry analysis of the lines after Ponceau S staining was used as
protein-loading control.Table 1
List of human primers used for RT–qPCR.
Primer Gene Position Sequence (5′ to 3′)
GPx1-qF GPX1
NM_000581.2
301–320 TCGGCTTCCCGTGCAACCAG
GPx1-qR 420–440 CGCACCGTTCACCTCGCACTT
GPx4-qF GPX4
NM_002085.3
403–422 CCTTCCCGTGTAACCAGTTC
GPx4-qR 587–609 ACTTGGTGAAGTTCCACTTGATG
Cat-qF CAT
NM_001752.3
1028–1053 TGGTAAACTGGTCTTAAACCGGAATC
Cat-qR 1159–1179 GGCGGTGAGTGTCAGGATAGG
Sod1-qF SOD1
NM_000454.4
430–451 TGTGGCCGATGTGTCTATTGAA
Sod1-qR 519–539 CACCTTTGCCCAAGTCATCTG
Sod2-qF SOD2
NM_001024465.1
708–728 GGGAGCACGCTTACTACCTTC
Sod2-qR 845–867 TCTTGCTGGGATCATTAGGGTAT
GSS-qF GSS
NM_000178.2
286–308 AGATGGACTTCAACCTGCTAGTG
GSS-qR 374–395 GTCAAAGAGACGAGCGGTAAAG
Apaf1-qF APAF-1
NM_013229.2
3105–3128 TGGCAGTGGTTGCTTTGTCCCAGT
Apaf1-qR 3190–3219 GGAGAAAACATCACACCATGAACC
CAACTT
Bax_qF BAX
NM_138764.4
229–251 GCGTCCACCAAGAAGCTGAGCGA
Bax_qR 401–424 TGCTGGCAAAGTAGAAAAGGGCGA
Bik-qF BIK
NM_001197.4
96–118 CTTGATGGAGACCCTCCTGTATG
Bik-qR 166–186 AGGGTCCAGGTCCTCTTCAGA
Rpl13A-qF RPL13A
NM_012423.3
541–563 CCTGGAGGAGAAGAGGAAAGAGA
Rpl13A-qR 642–666 TTGAGGACCTCTGTGTATTTGTCAA
GPX1, Glutathione peroxidase-1; GPX4, Glutathione peroxidase-4; Cat, Catalase; SOD-1,
Cu/Zn-Superoxide dismutase; SOD-2, Mn-Superoxide dismutase; GSS, Glutathione
synthetase; APAF-1, Apoptotic peptidase activating factor 1; BAX, BCL2-associated X
protein; BIK, Bcl-2-interacting killer; RPL13A, Ribosomal protein L13A. Primers were
designed using Primer3 software (v.0.4.0).2.10. Cell death analysis
Cell death was assessed in cell lysates by the release of cytochrome c
(cyt c) from the mitochondria, and by the caspase-9 and caspase-3
enzyme activity. The cytoplasmic cyt c releasewas determined bywest-
ern blot analysis by using the anti-cyt c primary antibody (Santa Cruz
Biotechnology) and anti-β-actin (Abcam) as protein-loading control.
Caspase-9/-3 activitieswere spectrophotometricallymeasured as previ-
ously reported [10].
2.11. Protein expression proﬁling by two dimensional electrophoresis
Protein samples were obtained in 20 mM Tris–HCl pH 7.6, 0.5 M
Sucrose, 0.15 M KCl, 10 μg/ml leupeptin, 2 μg/ml aprotinin, 10 mg/ml
PMSF and 20 mM DTT supplemented with the commercial Mini
EDTA-free protease inhibitor cocktail (Roche). Proteins were quantiﬁed
by the Bradford assay and 300 μg of total cellular proteins was used in
each isoelectrofocusing (IEF) strip (18 cm ReadyStrip™ IPG Strips
pH 3–10 nonlinear). The IEF program and the two dimensional electro-
phoresis (2-DE) conditions were performed as detailed in [14]. Gels
from 2-DE were stained with SYPRO Ruby and further digitalized with
the FX ProPlus Multiimager. The analysis of the differential intensity
spot and the spot volume, normalized by the total density in gels,
was quantiﬁed by using the PDQuest software (v.8.0.1) (Bio-Rad
Laboratories, California, USA). Protein samples from four independent
experiments were run in triplicate.
2.12. Identiﬁcation of differentially expressed proteins
Differentially expressed protein spots were excised from the prepar-
ative 2-D gel by using a ProPic workstation (Genomic Solutions Inc.,
Michigan, USA), digested with trypsin, and subjected to MALDI-TOF
analysis in the UCO-SCAI proteomics facility (Córdoba, Spain. Carlos III
Networked Proteomics Platform, ProteoRed-ISCIII) [14]. The conﬁrma-
tion of the results was performed by western blot, using 5 μg of total
cellular proteins and the primary antibodies anti-HSP60, anti-PDI,
anti-ADX Reductase and anti-PRDX3 (Santa Cruz Biotechnology).
2.13. Cathepsin D activity assay
Cathepsin D activity was measured in cell lysates with the use of
a commercial assay kit (Abcam) following the manufacturer recom-
mendations. Data were normalised by the cell number, which was
assessed immediately before the enzyme activity measurement.
2.14. Statistical analysis
Results were expressed as mean ± standard error. Data were
compared using the non-parametric method Kruskal–Wallis and the
Mann–Whitney's U test, searching for differences between groups
(n b 30). All tests and calculations were done with the statistical
package SPSS 15.0 for Windows (IBM). Statistical difference was set at
p ≤ 0.05. * Indicates statistically signiﬁcant differences between cell
lines for a same condition. # Indicates statistically signiﬁcant differences
between conditions (anti-Fas or L-NAME vs. basal; +L-NAME vs. anti-
Fas) for a same cell line.
3. Results
3.1. NOS-3 localizes in the mitochondrion outer membrane
The western blot analysis of NOS-3 in different subcellular fractions
showed an expression of the protein in membranes, cytoplasm and
mitochondria from 4TO-NOS cells (Fig. 1A). In addition, enzymatic
treatment of intact mitochondria with trypsin and proteinase-K
efﬁciently removed NOS-3 and TOM40 from mitochondria, but not
Fig. 1. NOS-3 localization in 4TO-NOS cells. (A) Subcellular localization of NOS-3 in 4TO-NOS. Effect of anti-Fas administration on the mitochondrial localization of NOS-3 (n = 3).
Densitometry of the lines corresponding to mitochondrial NOS-3 is shown. MTCO2 signal was used as loading control for cell lysate (CL), membrane fraction (MB) and mitochondrial
fraction (MT). NOS-3 signal in cytoplasm (CYT) was referred to the protein load. (B) Mitochondrial localization of NOS-3 assessed by western blot. Mitochondrial fraction was subjected
to enzymatic digestion with trypsin (6 or 20 μg/100 μg protein) or proteinase-K (PK, 10 or 40 μg/100 μg protein). (C) NOS-3 cellular localization by confocal microscopy. Green: MTCO2
protein. Red: NOS-3 protein. Blue: DAPI. Statistically signiﬁcant differences between cell lines* or between treatments# are marked.
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(Fig. 1B). The confocal immunoﬂuorescence study showed that NOS-3
was primarily localized in the plasma membrane and in the cellular
cytoplasm of the NOS-3-overexpressing cells (Fig. 1C). The mitochon-
drial localization of NOS-3 was not conﬁrmed by this approach.
In order to assess the effect of anti-Fas on the subcellular distribution
of NOS-3 and cell death susceptibility, we studied the mitochondrial
localization of the protein in the presence of the apoptosis inducer. As
shown in Fig. 1A, anti-Fas had a trend to an increased NOS-3 expression
in 4TO-NOS, which coincided with a reduced localization of the protein
in the mitochondrial fraction (0.24 vs. 0.06, p = 0.021).
3.2. Stable overexpression of NOS-3 does not affect the cell respiratory
capacity
In order to evaluate the role of NOS-3 overexpression on cellular
respiration, we analysed oxygen consumption associated with
mitochondrial complexes I (CI), II + III (CII + III) and IV (CIV) in the
4TO-NOS cell line. As shown in Fig. 2, NOS-3 overexpressionwas related
to a subtle increase in respiratory activity of CII + III (119%, p = 0.024),
without affecting oxygen consumption dependent of CI and CIV
(Fig. 2A). This resulted in a non-signiﬁcant increase of the endogenous
cellular respiratory capacity (Fig. 2B) and in a higher MMP (129%,
p = 0.004) (Fig. 2C). When the cell-permeable NOS inhibitor L-NAME
was added to the cell culture medium, an increase in oxygen consump-
tion dependent on CI and CII + III, in both 4TO (166% p = 0.014 and
118% p = 0.033, respectively) and 4TO-NOS cell line (154% p = 0.025
and 138%p=0.052, respectively)was observed (Fig. 2A). The induction
of apoptosis by anti-Fas led to a statistically signiﬁcant decrease in
oxygen consumption mostly due to 30% loss of CI activity (p = 0.011),
and reduced the endogenous respiratory capacity (5.4 vs. 6.3, p =
0.050) and maximum respiratory capacity (10.1 vs. 12.9, p = 0.050) in4TO-NOSwhen compared to 4TO cells (Fig. 2A and B). The simultaneous
administration of anti-Fas and L-NAME had a similar effect on oxygen
consumption as that caused by the sole addition of L-NAME on 4TO
cells. By contrast, in 4TO-NOS, L-NAME inhibited the effect of anti-Fas
on themitochondrial CI (p= 0.053). The oxygen consumption increase
induced by L-NAME in the presence of anti-FAS was paralleled byMMP
increase in the two cell lines.3.3. Nitro-oxidative stress and mtDNA copy number are enhanced in
4TO-NOS
The mitochondrial localization of NOS-3 in 4TO-NOS cells was
associated with increased levels of tyrosine nitration of mitochondrial
proteins (85.48 vs. 35.81, p = 0.050), which translates the production
of RNS (Fig. 3A). In addition, NOS-3 overexpressing cells accumulated
a higher concentration of nitric oxide end products in the cell culture
medium (Fig. 3B), and showed a general ROS production increase
(168%, p b 0.001 for DCF; 149%, p = 0.048 for DHE) (Fig. 3C) and an
up-regulation of antioxidant genes encoding for proteins superoxide
dismutase (SOD)-1 (154%, p = 0.032), SOD-2 (210%, p = 0.019),
catalase (149%, p = 0.021), glutathione peroxidase (GPX)-1 (235%,
p = 0.032), GPX-4 (155%, p = 0.032) and glutathione synthetase
(GSS) (167%, p = 0.034) (Fig. 3D). The administration of L-NAME did
not reduce oxidative stress in 4TO-NOS (Fig. 3C), but caused a reduction
ofmitochondrial protein nitration (Fig. 3A) and a lower accumulation of
nitrates andnitrites in the cell culturemedium (Fig. 3B), whichbalanced
the observed differences between 4TO-NOS and the control cell line
4TO. The nitro-oxidative stress related to NOS-3 overexpressionwas as-
sociated with an increased mtDNA copy number (148%, p b 0.001)
(Fig. 3E) and with a higher protein expression of mitochondrial CIV
(163%, p = 0.019) (Fig. 3F).
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culture medium of 4TO-NOS cells (1.25 vs. 4.12, p = 0.034) (Fig. 3B).
In addition, anti-Fas induced the antioxidant gene expression in 4TO
cells, but it had no additional effect on gene expression and oxidative
stress in the 4TO-NOS cell line (Fig. 3C and D).3.4. NOS-3 overexpression increases susceptibility to anti-Fas-induced cell
death
As shown in Fig. 4A, NOS-3 overexpression was associated with an
increased expression of pro-apoptotic genes Bax (164%, p = 0.003),
Bik (354%, p=0.002) and Apaf-1 (168%, p=0.002) at basal conditions.
This coincidedwith a higher localization of cyt c in the cytoplasm (168%,
p = 0.019), and the increase of caspase-9 (124%, p = 0.047) and
caspase-3 (166%, p = 0.011) associated activities (Fig. 4B and C). The
administration of anti-Fas stimulated Bik expression in 4TO (146%,
p = 0.010) and 4TO-NOS cells (563%, p = 0.007), without affecting
Bax or Apaf-1. In addition, anti-Fas caused an increase in the caspase-3
activity in both cell lines (153% and 318%, respectively; p b 0.050), as
well as a higher caspase-9 activity only in 4TO-NOS (229%, p =
0.034). There were no signiﬁcant differences in the release of cyt c
after incubation with anti-Fas.3.5. Comparative proteomic proﬁle of the 4TO-NOS cell line
The proteomic proﬁle of 4TO-NOS cells was analysed and further
compared to that of the control cell line 4TO, searching for differentially
expressed proteins that could be involved in the process of ROS produc-
tion and cell death observed at basal condition. The quantitative analysis
of the gels yielded 110 spots with signiﬁcantly altered expression. 56 of
these spots were identiﬁed by mass spectrometry as 42 different
proteins. The location of these spots in the master gel is shown in
Fig. 5A. Supplementary Fig. 1 shows a representative 2-D gel for each
condition. Differentially expressed proteins have been classiﬁed accord-
ing to their main biological functions (Table 2). Differences in proteins
involved in metabolism (11), cytoskeleton (2), RNA processing (5),
protein processing (8), protein degradation (6) and redox homeostasis
(10) were found. NOS-3 overexpression mainly affected the expression
of proteins involved in metabolism (8) and redox system (8). Among
the metabolic proteins, three were up-regulated proteins (+) involved
in the β-oxidation and glycolysis processes: medium and short-chain-
speciﬁc acyl-CoA dehydrogenases (+5.4/+2.8, respectively) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; +2.3). In the
second largest group of proteins deregulated by NOS-3 overexpression,
we found over-expression of proteins in both the cell anti-oxidant
system and the pro-oxidant system: thioredoxin-dependent peroxide
Fig. 3. Effect of NOS-3 overexpression on the cellular nitro-oxidative status and mitochondrial biogenesis. (A) Quantiﬁcation of protein nitration in the mitochondrial fraction by western
blot (n=3). (B) Accumulation of nitric oxide endproducts, nitrates andnitrites, in the cell culturemedium (n=3). (C) General ROS productionwas assessed byusing probesDCF (n=11
for basal and anti-Fas; n= 4 for L-NAME and+L-NAME) and DHE (n= 8). (D) Gene expression analysis of antioxidant proteins GPX-1, GPX-4, Catalase, SOD-1, SOD-2 and GSS (n= 4).
(E) MtDNA copy number quantiﬁcation (n = 9). (F) Expression analysis of proteins from the mitochondrial respiratory complexes (n = 3 or 4). B indicates basal conditions. +L-NAME
(+L-N) indicates treatment with anti-Fas (A-F) plus L-NAME (L-N). Data are mean ± SEM. Statistically signiﬁcant differences between cell lines* or between treatments# are marked.
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Fig. 4. Effect of anti-Fas administration on cell death. (A) Gene expression analysis of pro-apoptotic proteins APAF-1, BAX and BIK (n = 4). (B) Cytoplasmic expression of cyt c. It is
represented the cyt c/β-actin ratio versus the control cell line 4TO at basal condition (n=3). (C) Caspase-9 and caspase-3-associated activities (n= 4). Data aremean± SEM. Statistically
signiﬁcant differences between cell lines* or between treatments# are marked.
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+2.1), superoxide dismutase [Mn] mitochondrial (SOD2; +3.2) and
NADPH:adrenodoxin oxidoreductase mitochondrial (ADX reductase or
AR; +3.7). Cathepsin D (CatD) was identiﬁed in two different spots as
a protease upregulated by NOS-3 overexpression (+2.3 and +1.9),
and in a third additional spot that was only detected in 4TO-NOS cells.
In the presence of anti-Fas, the cell lines 4TO and 4TO-NOS showed
differences in the protein expression proﬁle as a consequence of NOS-
3 overexpression. The differentially expressed proteins were mainly
involved in protein processing (6), protein degradation (6) and redox
homeostasis (5). The apoptosis inductor did not modify the expression
pattern of CatD in 4TO-NOS.
In order to verify 2-D PAGE/MS results, we randomly chose four
proteins from those previously identiﬁed by MS, and conﬁrmed their
relative expression deregulation by western blot analysis. These pro-
teins were heat shock protein 60 (HSP60), protein disulﬁde isomerase
(PDI), PRDX3 and AR (Fig. 5B).
3.6. Cathepsin D expression, but not its activity, is associatedwith cell death
Next, we investigated the role of CatD in NOS-3 overexpressing cells.
As shown in Fig. 6, the overexpression of CatD in 4TO-NOS cells wasaccompanied by the increase of its enzymatic activity (176%, p =
0.020) (Fig. 6A). The inhibition of CatD activity by 20 μM pepstatin A
(Fig. 6B) had no effect on cell growth (Fig. 6C) but it was associated
with the activity increase of caspase-3 (1.23 fold, p = 0.050) and
caspase-9 (1.22 fold, p = 0.037) in 4TO-NOS when compared to basal
condition (Fig. 6D and E). At 50 μM, pepstatin A caused a signiﬁcant
increase in cell doubling time in the 4TO-NOS cell line (66.2 vs. 47.5,
p=0.021) (Fig. 6F), whichwas paralleled by a higher caspase-3 activity
(1.73 fold increase, p = 0.047) (Fig. 6G). The addition of anti-Fas to the
cell culture medium did not affect CatD activity in the cell lines 4TO or
4TO-NOS (Fig. 6A). By contrast, the simultaneous administration of
anti-Fas and pepstatin A resulted in the activity increase of caspase-3
(p = 0.050) in the cell line 4TO-NOS when compared to the condition
of anti-Fas addition (Fig. 6D).
4. Discussion
We have previously shown that stable NOS-3 overexpression
induces the oncoprotein p53 and the cell death receptor Fas, in HepG2
cells as well as in tumours subcutaneously developed in a xenograft
mouse model [10]. Indeed NOS-3 up-regulation has been suggested
as a candidate antiproliferative mechanism in hepatocarcinoma cells.
Fig. 5. Differentially expressed proteins in 4TO-NOS cells. (A) 2-D Master gel. Deregulated protein spots in 4TO-NOS are marked and numbered. (B) Western blot analysis of proteins
60 kDa heat shock protein mitochondrial (HSP60), protein disulﬁde-isomerase (PDI), thioredoxin-dependent peroxide reductase mitochondrial (PRDX3) and NADPH:adrenodoxin
oxidoreductase mitochondrial (AR). A representative image of a Ponceau-stained membrane used in the western blot analysis is shown. Data are mean ± SEM. Statistically signiﬁcant
differences between cell lines* or between treatments# are marked.
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cell death promoted by NOS-3 overexpression. In addition, we have ex-
plored the susceptibility to anti-Fas-induced cell death in the 4TO-NOS
cell line. Fig. 7 summarizes the main ﬁndings of this study about cell
death mechanisms induced by NOS-3 overexpression in a representa-
tive scheme.
As NOS-3 is expressed in mitochondria [3], and it is well known the
key role of this organelle in apoptotic cell-death, we analysed the
expression pattern of the protein in 4TO-NOS cells. We found that
NOS-3 is mainly localized in the plasma membrane and cytoplasm,
which agrees with earlier studies in which NOS-3 was present in the
Golgi complex and in cell–cell contacts of conﬂuent cells [18]. In addi-
tion, we observed that NOS-3 colocalized with mitochondrial proteins,
and that NOS-3 was cleaved from the mitochondria by a protease treat-
ment, suggesting its association with the outer mitochondrial mem-
brane. This was consistent with the high levels of tyrosine nitration of
mitochondrial proteins observed in NOS-3 overexpressing cells. Due to
the inhibitory effect that NO has on the oxidative phosphorylation
(OXPHOS) system, its ability to diffuse through cell membranes, and
the ﬁnding that NOS-3 is localized in the mitochondria, we next inves-
tigated the respiratory capacity of the 4TO-NOS cell line. Unexpectedly,
NOS-3 overexpression did not cause any relevant effect on the mito-
chondrial respiration. Despite this, 4TO-NOS cells showed increased
levels of oxidative stress that coincided with the expression increase
of genes involved in ROS detoxiﬁcation and with a high mtDNA copy
number, compared to the control cell line 4TO. In this regard, previous
studies have shown that mtDNA biogenesis may be regulated by oxida-
tive stress under different conditions [19], and that NO is able to trigger
mitochondrial biogenesis in culture cells [20]. The increase in mtDNA
copy number was paralleled by a higher expression of the mtDNA-
encoded protein MTCO2, which may be an attempt by 4TO-NOS cells
to adapt to the conditions of NO overproduction.With the aim to link these previous observations to NOS-3 overex-
pression, we additionally used L-NAME. This commonly used NOS
inhibitor effectively suppressed the effects of NOS-3 overexpression
relating to the accumulation of NO end products and the nitration of
mitochondrial proteins. However, L-NAME was not effective in sup-
pressing oxidative stress induced by NOS-3 overexpression. Conversely,
L-NAME caused an increased activity of the OXPHOS system, which is
closely related to ROS production [21] and may be a consequence of
the inhibitory effect of NO on the respiration [8]. Nevertheless, L-
NAME caused a similar effect in both cell lines 4TO and 4TO-NOS, thus
indicating that NOS-3 overexpression has no relevant role in mitochon-
drial respiration. This result was conﬁrmed when wemeasured cellular
respiration in non-permeabilized cells. Thus, despite the inhibitory
effect of NO in respiration, the apoptosis induction by NOS-3 overex-
pression did not occur through dysfunction of the OXPHOS system.
We have previously shown that 4TO-NOS cell line has increased
levels of p53 protein [10], which is an important cell cycle regulator
able to initiate apoptosis in response to oxidative stress [22]. Indeed,
p53 activity has been related to the expression regulation of several
apoptotic genes [23]. In the present study, NOS-3 overexpression was
associated with the expression increase of pro-apoptotic genes such as
Bax, Bik and Apaf-1, and with a consequent release of cyt c into the
cytoplasm and the activity increase of caspase-9 and caspase-3. These
results would explain the spontaneous apoptosis showed by 4TO-NOS
at basal condition. In addition, NOS-3 overexpression was related to
MMP increase, consistent with the induction of apoptosis through the
mitochondrial membrane hyperpolarization.
When we analysed the effect of anti-Fas in the 4TO-NOS cell line,
we found that the apoptosis inductor caused a lower localization of
NOS-3 in the mitochondria. This observation coincided not only
with a decrease in the cellular content of nitrated mitochondrial pro-
teins, but also with a non-relevant reduction in respiratory capacity
Table 2
Differentially expressed protein spots between cell lines 4TO and 4TO-NOS (NOS) identiﬁed by mass spectrometry. Differential expression ratio in bold indicates statistically signiﬁcant
expression with p b 0.01. The rest with p b 0.05. In the fold change box ‘NOS’ indicates ‘only expressed in 4TO-NOS’; + indicates anti-Fas treatment.
Biological Classiﬁcation Protein name
(Accession number)
Molecular function Spot N° MS IS NOS
vs.
4TO
NOS+
vs.
4TO+
4TO+
vs.
4TO
NOS+
vs.
NOS
Metabolism Enoyl-CoA hydratase, mitochondrial (P30084) β-oxidation 46 589 470 1.3 1.7
Medium-chain-speciﬁc acyl-CoA dehydrogenase
mitochondrial (B7Z9I1)
27 379 290 5.4 −1.5
Short/branched chain-speciﬁc acyl-CoA dehydrogenase
mitochondrial (B4DQ51)
28 215 155 2.8 1.4
GAPDH (P04406) Glycolysis 65 124 77 2.3 3.0
Alpha-enolase (P06733) 18 136 97 1.5
D-3-phosphoglycerate dehydrogenase (O43175) Amino acids 8 269 157 −2.1 −1.8
Retinal dehydrogenase 1 (P00352) Retinol 10 651 543 −3.0 −2.0 1.7
Abhydrolase domain-containing protein 14B (B4DQI4) Hydrolase 56 72 39 −2.5 2.0
Sulfurtransferase (J3KPV7) Transferase 64 264 195 1.5 −1.5
AMP deaminase 2 (Fragment) (H0Y360) IMP 104 48 5.2
Adenylate kinase 2, mitochondrial (F8VY04) Energy 109 141 121 1.5
RNA processing hnRNPL (P14866) hnRNP/28S component 4 132 111 −2.8
5 206 173 −1.9
hnRNPH (P31943) 12 674 569 −1.6
hnRNPD0 (H0YA96) 24 273 229 −1.4
hnRNPK (P61978) 50 360 314 −2.1
28S RNPS22, mitochondrial (P82650) 63 278 185 2.6
Protein degradation Cytosol aminopeptidase (P28838) Proteolysis/Protein stability 11 573 417 −2.1 −2.0
Aminoacylase-1 (Q03154) 25 135 79 2.6 −1.9
Serine protease HTRA2, mitochondrial (O43464) 31 249 189 2.6
Isochorismatase domain-containing protein 2,
mitochondrial (Q96AB3)
73 264 217 3.7 2.3
Cathepsin B (P07858) 37 288 204 1.4 1.8
54 407 332 −1.5 1.3
Cathepsin D (P07339) 41 498 389 NOS NOS+
42 598 475 2.3 2.8
44 268 223 1.9 2.1
Protein processing 60 kDa heat shock protein, mitochondrial (P10809) Chaperone/Protein assembly 14 130 114 −4.1 −3.7
15 415 350 −1.2 −1.5
16 136 2.0 3.9
17 287 210 −1.9
78 kDa glucose-regulated protein (P11021) 32 98 78 2.1
48 513 434 −1.2 −1.3
66 610 463 −1.8
86 157 140 1.8 −1.4
93 131 113 −1.5 −1.6
Heat shock protein beta-1 (P04792) 47 300 255 1.8
Protein DJ-1 (Q99497) 57 183 102 1.3
GrpE protein homolog 1, mitochondrial (Q9HAV7) 58 313 271 2.5
Stress-70 protein, mitochondrial (P38646) 68 441 386 1.8
ATP synthase mitochondrial F1 complex assembly
factor 1 (H0YD21)
38 70 8.4 3.1
Calreticulin (P27797) 100 133 107 −1.5
Skeleton Actin, cytoplasmic 2 (P63261) 26 761 614 1.7
43 119 103 1.7
Microtubule-actin cross-linking factor 1,
isoforms 1/2/3/5 (F5GZL7)
92 48 11 −2.6
Redox Homeostasis Thioredoxin (Fragment) (H7BZJ3) Oxido-reductase/Isomerase 36 148 128 1.4 −1.2
Thioredoxin-dependent peroxide (E9PH29) 51 353 313 3.2 3.6
NADPH:adrenodoxin oxidoreductase,
mitochondrial (P22570)
55 582 506 3.7 3.1
Peroxiredoxin-2 (P32119) 62 800 323 2.1 1.4 1.7
Peroxiredoxin-1 (Q06830) 72 407 279 2.0
SOD [Mn] mitochondrial (P04179) 74 450 375 3.2
Aldo-keto reductase family 1 member C1 (Q04828) 85 328 258 6.9 2.0 2.8
Protein disulﬁde isomerase family A, member 3,
isoformCRA_b (G5EA52)
9 943 636 −5.1 3.7
13 350 266 −2.1 −1.7
67 406 299 1.9
Protein disulﬁde-isomerase (H7BZ94) 30 196 149 −2.4
Protein disulﬁde-isomerase (I3L2P8) 107 91 −2.4
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NOS-3 overexpressing cells showed increased susceptibility to anti-
Fas-induced cell death, which was mediated by the activity increase
of caspase-9 and caspase-3. By contrast, apoptosis induction in the
control cell line 4TO was only related to the increase of caspase-3
activity. Therefore, while in the control cell line anti-Fas induced
apoptosis through the extrinsic pathway, an additional activationof both the extrinsic and the mitochondrial apoptotic pathways
was observed in 4TO-NOS, which was higher than that induced by
NOS-3 overexpression alone.
In order to identify intermediates that could be involved in the
process of cell death in 4TO-NOS, we analysed the protein expression
proﬁle compared to the control cell line 4TO. We identiﬁed proteins
with different biological functions, whose differential expression is
Fig. 6. Cathepsin D activity and cell death. (A) CatD activity in cell lysates (n= 4). (B) CatD activity inhibition curve by pepstatin A. Normal CatD activity in control cell line 4TO ismarked.
(C) Effect of 20 μM pepstatin A on cell growth (n = 3) and (D) caspase-3 (n = 3) and (E) caspase-9 (n = 3) activities. (F) Effect of 50 μM pepstatin A on cell growth (n = 4) and
(G) caspase-3 activity (n = 5) at 48 h. +PA indicates treatment with pepstatin A (PA) plus anti-Fas. Data are mean ± SEM. Statistically signiﬁcant differences between cell lines* or
between treatments# are marked.
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metabolic proteins, it should be noted that nitrosylation is a posttrans-
lational modiﬁcation by which NO can reversibly regulate β-oxidation[24] and glycolysis [25]. In particular, GAPDH activity may be regulated
by nitrosylation, being its hyperactivation an adaptive pro-survival
response under pro-oxidant conditions [26]. By contrast, nitrosylated
Fig. 7. Cell death mechanisms in 4TO-NOS cells. NOS-3 overexpression was associated with cellular nitro-oxidative stress through the respiratory capacity increase of mitochondrial
complex II + III and the tyrosine nitration of mitochondrial proteins. Nitro-oxidative stress induced by NOS-3 overexpression in HepG2 cells was related to 1) the activation of the
mitochondrial-associated caspase pathway through the expression increase of pro-apoptotic genes and the release of cyt c into the cytoplasm; 2) the expression increase of proteins
adrenodoxin reductase mitochondrial (AR) and cathepsin D (CatD); and 3) higher susceptibility to anti-FAS induced cell death through activation of the apoptosis pathways. The
expression regulation of these factors including Bax, Bik, Apaf-1, AR, CatD and FAS, has been previously related to p53, which is upregulated in 4TO-NOS cells. Both, ROS production
and protein tyrosine-nitration have been associatedwith p53 regulation and apoptosis. ARmay contribute to oxidative stress. Pepstatin A (PA) induces apoptosis likely through the release
of CatD from lysosomes.
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ing to cell death [27]. In this regard, we have previously reported that
NOS-3 overexpression increases the proﬁle of S-nitrosylated proteins
[14], and induces p53 expression in HepG2 [10], reducing cell survival.
Adding anti-Fas to the cell culture induced GAPDH expression in the
control cell line, thus abolishing the difference induced by NOS-3
overexpression.
In the second largest group of identiﬁed proteins, we found over-
expression of proteins involved in the cellular antioxidant system. This
agreed with the gene expression proﬁle of 4TO-NOS. Thus, the up-
regulation of antioxidant enzymes through activation of the ROS-
sensitive signalling pathway is well established. Peroxiredoxins are
involved in the attenuation of the generation of reactive oxygen/nitro-
gen species and NO [28,29], and may be regulated by nitrosylation
[30]. Moreover, we detected a signiﬁcant increase of AR in the 4TO-
NOS cell line. AR is a mitochondrial oxidoreductase that catalyses the
oxidation of NADPH, acting as the ﬁrst electron transfer protein of
mitochondrial P450 systems. This system can work as a futile NADPH
oxidase, oxidizing NADPH in the absence of substrate, leaking electrons
to O2 and generating ROS [31]. ARwas particularly interesting because it
participates in the p53-mediated apoptosis by oxidative stress [32].
Here, increase of AR expression induced by NOS-3 overexpression coin-
cided with ROS production, p53 accumulation [10], and apoptosis
induction through the expression of pro-apoptotic genes that are regu-
lated by p53. In agreement with the oxidative status of the cell lines,
anti-Fas did not change the expression proﬁle of AR in 4TO and 4TO-
NOS.
The protease CatD was identiﬁed in two up-regulated spots, as well
as in a third additional spot only detected in 4TO-NOS, which probably
belongs to a chemical modiﬁcation of the protein. Indeed the posttrans-
lational modiﬁcation of CatD has been implicated in tissue remodelling
occurring after lactation [33]. In accordancewith the protein expression
analysis, the stable overexpression of NOS-3 increased the CatD activity
in HepG2 cells. These results were also related to p53 expression [10,34]and agree with previous observations in which CatD participated in the
apoptosis induction by NO [35]. Furthermore, it has been reported that
the genetic and pharmacological inhibition of CatD is effective in
blocking apoptosis in several different models, including anti-Fas in-
duced cell death [36]. Despite this, anti-Fas did not induce CatD activity
in the control cell line 4TO. To better understand the role of CatD in our
cell model of NOS-3 overexpression, we analysed cell death-related
parameters in the presence of pepstatin A. At 20 μM, pepstatin A was
able to inhibit CatD activity in 4TO-NOS below the observed level in
the control cell line 4TO. However, it did not affect the growth of 4TO
or 4TO-NOS cells. As expected, 20 μM pepstatin A failed to suppress
the caspase-3 activity induced by anti-Fas in 4TO control cells, thus
indicating that CatD activity is not essential for Fas-induced cell death
in HepG2. These results differ from those previously published about
the participation of the protease in apoptotic systems triggered by the
activation of cell surface receptors [36,37]. On the other hand, CatD
activity inhibition in 4TO-NOS caused a signiﬁcant increase in the
caspase-3 activity, which was signiﬁcantly higher to that caused by
the NOS-3 overexpression at both in basal conditions and after anti-
Fas addition. Thus, CatD activity induced by NOS-3 overexpression
seemed to be associated with an anti-apoptotic effect rather than pro-
apoptotic. In this regard, an anti-apoptotic role for CatD cannot be ex-
cluded since it is overexpressed inmanymalignant tumours and it is as-
sociated with cancer spreading and clinical outcome, and its expression
is conditional on apoptosis-associated protein phenotype [38].
Furthermore, the protease may promote cell survival under oxidative
stress [39]. Despite of this, Beaujouin et al. reported that CatD overex-
pression by cancer cells exerts a pro-apoptotic effect that is independent
on its catalytic activity. Thus, cytosolic CatD would stimulate apoptosis
by interacting with the apoptotic machinery rather than by cleaving
speciﬁc substrates [40]. If so, we could not rule out a pro-apoptotic
role for CatD in our cell model of NOS-3 overexpression since the CatD
inhibitor pepstatin A stimulates the protease release from lysosomes
at the commonly used dose of 50 μM [41]. In such a scenario, the
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A administration could be a consequence of a higher cytoplasmic local-
ization of CatD, and not an effect caused by the CatD activity inhibition.
This is consistent with the increased caspase-9 activity induced by
pepstatin A in NOS-3 overexpressing cells, since inactive pro-caspase-
9 is activated through the mitochondrial death pathway. Indeed,
50 μM pepstatin A caused a signiﬁcant slowing down of cell growth in
4TO-NOS.
In conclusion, NOS-3 overexpression promoted AR and CatD up-
regulation in a process related to oxidative stress generation and
apoptosis induction. These observations agree with previous studies
where both enzymeswere associatedwith apoptosis, andwere regulat-
ed by p53. Thus, AR and CatD emerge as new targets that could be
involved in the reduction of cell survival in NOS-3 overexpressing
cells, and join the list of proteins that we previously identiﬁed [14].
Overall, NOS-3 overexpression caused a higher sensitivity to anti-Fas-
induced cell death through the upregulation of pro-apoptotic genes
and the increase in caspase-9 and caspase-3 activities, without affecting
AR and CatD activity and/or expression. Since the pro-apoptotic effect
of CatD overexpression may not be related to its enzymatic activity,
we cannot exclude a signiﬁcant role for this protein in the apoptosis
induction by NOS-3 overexpression. The potential role of the GAPDH
increase in the regulation of p53 activity in 4TO-NOS cells remains
to be determined. Similarly, it remains to be established the posttrans-
lational modiﬁcation affecting CatD activity during the NOS-3
overexpression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.02.015.
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